Overview

The Effect of Oxymetazoline Gel on Anal Pressure and Incontinence in Spinal Cord Injury Patients

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
0
Participant gender:
All
Summary
This is an double blinded, cross-over study to determine the effect of Oxymetazoline gel on anal resting pressure and fecal incontinence in patients with spinal cord injury. Approximately 17 subjects are expected to complete this 10 weeks study that will include two treatment periods of 4 weeks each, and one 2 weeks wash out period.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
RDD Pharma Ltd
Treatments:
Oxymetazoline
Phenylephrine
Criteria
Inclusion Criteria:

- Signed written informed consent.

- Male or female subjects 18 to 55 years of age;

- Spinal Cord Injury that occurred at least 3 months from randomization day and less
than 3 years from randomization day.

- At least 4 unwanted/unexpected incontinent events/week

Exclusion Criteria:

- Known allergy to Oxymetazoline or silicone.

- Pregnancy or lactation.

- Active cardiovascular or cerebrovascular disease including unstable angina, myocardial
infarction, transient ischemic attacks/stroke, clinically significant arrhythmia,
congestive heart failure, or cardiac valve abnormalities;

- Type 1 diabetes mellitus;

- Insulin treated type 2 diabetes mellitus;

- Renal insufficiency.

- Liver insufficiency.

- Malignant disease within 5 years of screening;

- History of rectal surgery.

- History of HIV, hepatitis B, hepatitis C.

- Has upon physical examination a rectal deformation or signs of rectal disease such as
fissure, bleeding hemorrhoids, fistula, infection or space occupying lesion.

- Has used, in the last 1 week, drugs that may affect blood coagulation, such as Aspirin
(at a dose above 500 mg/day), Warfarin, Sintrom, Enoxaparin, Nadroparin, Heparin,
Clopidogrel, Ticlopidine.

- Hypertension (blood pressure over 150/105 mm Hg in screening visit)

- Unable to understand the use instruction, as judged by the investigator.